CANBERRA, Dec. 19 (Xinhua) -- A "revolutionary" cancer drug that supercharges immune cells to hunt and kill cancer cells has been approved for human use in Australia.

The Therapeutic Goods Administration (TGA) on Wednesday announced that CAR-T therapy has been approved for use in pediatric and young adult patients with B-cell precursor acute lymphoblastic leukemia (ALL) and adults with diffuse large B cell lymphoma (DLBCL).

CAR-T therapy trains immune cells to fight and kill cancer cells by first extracting them from a patient's body to genetically re-engineer them before infusing them back into the body.

Prior to the TGA approving the treatment, patients with aggressive blood cancers who had exhausted all other treatments had been traveling overseas to be treated.

Daniel Clarke, 45, traveled with his family to the United States so he could receive CAR-T treatment for his DLBCL. Within one month his cancer had vanished.

"I felt like someone had just handed my life back to me," he told Fairfax Media on Wednesday.

"It has all happened so quickly. Late September we (went to Boston) not knowing what to expect, hoping for the best, fearing the worst. Then come November I was in complete remission."

Global pharmaceutical giant Novartis owns the therapy and has already increased production to keep up with global demand.

"We are focused on ramping up capacity at our U.S. and Switzerland facilities and we recently announced a collaboration agreement for additional manufacturing capacity with Fraunhofer (Germany) and CellforCure (France)," spokesperson Lauren Carey said.

"These additional manufacturing facilities are intended to support production on a global scale."

However, CAR-T therapy is not classified as a "drug", so it cannot be subsidized by the Pharmaceutical Benefits Scheme.

Patients who undergo the treatment in Australia face an out-of-pocket cost of up to 598,000 Australian dollars.

Greg Hunt, Australia's Minister for Health, has flagged his intention to have the treatment subsidized as soon as possible.